Dr. Britt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4715 Arapahoe Avenue
Boulder, CO 80303Phone+1 303-385-2000- Is this information wrong?
Summary
- Dr. Gregory Britt is a practicing board-certified hematologist and medical oncologist at Rocky Mountain Cancer Center in Boulder, CO. Previously, he was medical director of the Cancer Centers of Colorado in Denver, CO, where he also served as Section Chief of Hematology and Medical Oncology at Saint Joseph Hospital, Denver.
His background and interests include: pharmaceutical clinical trials, healthcare quality, external peer review, and medicolegal consulting.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Tufts Medical CenterResidency, Internal Medicine, 2004 - 2007
Georgetown University School of MedicineClass of 2004
Certifications & Licensure
CO State Medical License 2013 - 2025
MA State Medical License 2006 - 2017- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012
Publications & Presentations
PubMed
- 2 citationsTreatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes.Leah Wells, Michael Cerniglia, Sarah Hall, Audrey C Jost, Gregory Britt> ;Journal of Immunotherapy and Precision Oncology. 2022 May 1
- 145 citationsThe Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR MutationsStephanie Heon, Beow Y. Yeap, Neal I. Lindeman, Victoria A. Joshi, Mohit Butaney, Gregory J. Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, Bruce E. Johnson> ;Clinical Cancer Research. 2012 Jun 25
- 1 citationsCase series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancerGregory J. Britt, Elizabeth M. Gaughan, Kim Nguyen, Jeremy L. Warner, Michael A. Goldstein, Mark S. Huberman, Daniel B. Costa> ;Journal of Thoracic Disease. 2011 Jan 5
- Join now to see all
Professional Memberships
- Member
Industry Relationships
- Parexel International, CROClinical Data Associate/Manager. Serious adverse event lead for global phase III trials.1998 - 2000
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
